Anifrolumab — Membership Pricing

Other medications in Rheumatology

• Baricitinib
• Belimumab
• Canakinumab
• Deucravacitinib
• Etanercept
• Filgotinib
• Guselkumab
• Ixekizumab

About Anifrolumab

Anifrolumab (brand name Saphnelo) is an innovative biologic medication offering a new treatment pathway for adults living with moderate to severe systemic lupus erythematosus (SLE). As a significant advancement in lupus care, understanding its role and cost is crucial. TheDrugClub is dedicated to helping members manage their prescription expenses, potentially making vital treatments like anifrolumab more accessible through our savings program.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Anifrolumab is approved for (FDA label)

SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.

Source: Read the full FDA label on DailyMed. Label effective date: April 24, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Anifrolumab (FDA label)

Intravenous Infusion • Injection: 300 mg/2 mL (150 mg/mL) as a clear to opalescent, colorless to slightly yellow solution in a single-dose vial. Subcutaneous Injection • Injection: 120 mg/0.8 mL as a clear to opalescent, colorless to slightly yellow solution in a single-dose prefilled syringe or single-dose autoinjector (SAPHNELO PEN). Intravenous Infusion: • Injection: 300 mg/2 mL (150 mg/mL) in a single-dose vial. ( 3 ) Subcutaneous Injection: • Injection: 120 mg/0.8 mL in a single-dose prefilled syringe or single-dose autoinjector (SAPHNELO PEN). ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d6203302-2128-41a7-b0b4-0e6c0704d4dc. SPL document ID: 810dc1a8-73e1-41fc-874f-2dd1d8ed1429. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Anifrolumab (FDA label)

The following clinically significant adverse reactions are also discussed elsewhere in the labeling: • Serious Infections [see Warnings and Precautions (5.1) ] • Hypersensitivity Reactions Including Anaphylaxis [see Warnings and Precautions (5.2) ] • Malignancy [see Warnings and Precautions (5.3) ] Most common adverse drug reactions (incidence ≥5%) are nasopharyngitis, upper respiratory tract infections, bronchitis, infusion related reactions, herpes zoster and cough. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: d6203302-2128-41a7-b0b4-0e6c0704d4dc. SPL document ID: 810dc1a8-73e1-41fc-874f-2dd1d8ed1429. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Anifrolumab (FDA label)

SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia [see Warnings and Precautions (5.2) ] . SAPHNELO is contraindicated in patients with a history of anaphylaxis with anifrolumab-fnia. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d6203302-2128-41a7-b0b4-0e6c0704d4dc. SPL document ID: 810dc1a8-73e1-41fc-874f-2dd1d8ed1429. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Anifrolumab (FDA label)

• Serious Infections: Serious and sometimes fatal infections have occurred in patients receiving SAPHNELO. SAPHNELO increases the risk of respiratory infections and herpes zoster. Avoid initiating treatment during an active infection. Consider the individual benefit-risk if using in patients with severe or chronic infections.

Source: FDA prescribing information (DailyMed). Set ID: d6203302-2128-41a7-b0b4-0e6c0704d4dc. SPL document ID: 810dc1a8-73e1-41fc-874f-2dd1d8ed1429. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Anifrolumab (FDA label)

No formal drug interaction trials have been conducted.

Source: FDA prescribing information (DailyMed). Set ID: d6203302-2128-41a7-b0b4-0e6c0704d4dc. SPL document ID: 810dc1a8-73e1-41fc-874f-2dd1d8ed1429. Label effective date: April 24, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.